ADGRL3 (LPHN3) variants predict substance use disorder

Biochemistry, Genetics and Molecular Biology

• Comorbidity 11%
• Genetic Determinism 11%
• Genetic Model 11%
• Genetics 22%
• Hyperactivity 77%
• Pharmacogenetic Testing 11%
• Recursive Partitioning 22%
• Substance Use 100%

Neuroscience

• Attention Deficit Hyperactivity Disorder 77%
• Clinical Assessment 11%
• Comorbidity 11%
• Conduct Disorder 11%
• Disruptive Behavior 11%
• Oppositional Defiant Disorder 11%
• Physical Dependence 100%

Immunology and Microbiology

• Comorbidity 50%
• Pharmacogenetic Testing 50%
• Susceptibility 100%